{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:35:39Z","timestamp":1789990539417,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T00:00:00Z","timestamp":1248912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Methotrexate (MTX) is the most commonly used disease\u2010modifying antirheumatic drug (DMARD) in the management of rheumatoid arthritis (RA). MTX is transported into cells, where additional glutamate moieties are added and it is retained as MTX polyglutamates (MTXGlu [referred to as a group as MTXGlu<jats:sub>n<\/jats:sub>]). There is large interpatient variability in MTXGlu<jats:sub>n<\/jats:sub>concentrations. This study was undertaken to determine nongenetic factors that influence red blood cell (RBC) MTXGlu<jats:sub>n<\/jats:sub>concentrations in patients receiving long\u2010term stable low\u2010dose oral MTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred ninety\u2010two patients receiving long\u2010term oral MTX for the treatment of RA were recruited. Trough MTXGlu<jats:sub>n<\/jats:sub>concentrations were measured by high\u2010performance liquid chromatography. Univariate analysis was performed to determine variables influencing MTXGlu<jats:sub>n<\/jats:sub>concentrations. Backward stepwise multivariate regression analysis was done to determine variables that affect individual MTXGlu<jats:sub>n<\/jats:sub>concentrations; variables with<jats:italic>P<\/jats:italic>values of &lt;0.1 in the univariate analysis for any MTXGlu<jats:sub>n<\/jats:sub>were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Univariate analysis revealed that increased age, lower estimated glomerular filtration rate (GFR), higher MTX dosage, longer duration of MTX treatment, and use of prednisone were associated with significantly higher MTXGlu<jats:sub>n<\/jats:sub>concentrations. Smokers had significantly lower concentrations of MTXGlu<jats:sub>3<\/jats:sub>, MTXGlu<jats:sub>3\u20135<\/jats:sub>, and MTXGlu<jats:sub>1\u20135<\/jats:sub>. Sex, rheumatoid factor and anti\u2013cyclic citrullinated peptide status, RBC folate level, and body mass index had no significant effect on MTXGlu<jats:sub>n<\/jats:sub>levels. Concomitant use of other DMARDs was associated with lower MTXGlu<jats:sub>2<\/jats:sub>levels, and treatment with nonsteroidal antiinflammatory drugs was associated with lower MTXGlu<jats:sub>3<\/jats:sub>and MTXGlu<jats:sub>1\u20135<\/jats:sub>concentrations. Multivariate regression analysis revealed that age, MTX dosage, and estimated GFR were the major determinants of MTXGlu<jats:sub>n<\/jats:sub>concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Large interpatient variability in MTXGlu<jats:sub>n<\/jats:sub>concentrations can be explained, at least in part, by a combination of factors, particularly age, MTX dosage, and renal function. There are complex interactions between smoking, RBC folate levels, and concentrations of MTXGlu<jats:sub>n<\/jats:sub>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.24653","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T15:15:42Z","timestamp":1248966942000},"page":"2248-2256","source":"Crossref","is-referenced-by-count":94,"title":["Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long\u2010term methotrexate treatment"],"prefix":"10.1002","volume":"60","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.729"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/28.5.422"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20460"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22129"},{"key":"e_1_2_7_6_2","first-page":"313","article-title":"Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis","volume":"17","author":"Angelis\u2010Stoforidis P","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24034"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.15.4881"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2360193"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630030-00002"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.2.110"},{"key":"e_1_2_7_14_2","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","author":"Rheumatoid Arthritis Clinical Trial Archive Group","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_7_15_2","first-page":"1903","article-title":"Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis: a comparison with young patients","volume":"24","author":"Bressolle F","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.12.944"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90786-5"},{"key":"e_1_2_7_19_2","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?","volume":"15","author":"Ahern M","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.69"},{"key":"e_1_2_7_21_2","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5mg","volume":"22","author":"Kremer JM","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20375"},{"key":"e_1_2_7_23_2","first-page":"2077","article-title":"Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate","volume":"29","author":"Carmichael SJ","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086264"},{"key":"e_1_2_7_25_2","first-page":"1670","article-title":"The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukaemia","volume":"33","author":"Zager RF","year":"1973","journal-title":"Cancer Res"},{"key":"e_1_2_7_26_2","first-page":"801","article-title":"Interaction of chemotherapeutic agents with methotrexate and 5\u2010fluorouracil and its effects on de novo DNA synthesis","volume":"35","author":"Bruckner HW","year":"1975","journal-title":"Cancer Res"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-3565(25)39209-8","article-title":"Influence of concomitant aspirin or prednisone on methotrexate synovial fluid concentration","volume":"243","author":"Stewart CF","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_28_2","first-page":"263","article-title":"Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients","volume":"20","author":"Lafforgue P","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.053"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20553"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.8.463"},{"key":"e_1_2_7_32_2","first-page":"861","article-title":"Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?","volume":"23","author":"Papadopoulos NG","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200102)44:2<323::AID-ANR49>3.0.CO;2-C"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065060"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken057"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90651-4"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90013-9"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0442-x"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.24653","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.24653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:40:02Z","timestamp":1739288402000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.24653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,30]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/art.24653"],"URL":"https:\/\/doi.org\/10.1002\/art.24653","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,30]]}}}